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A trial fibrillation (AF) is a common arrhythmia asso- ciated with a broad spectrum of underlying diseases 
that include systemic hypertension, rheumatic heart dis- 
ease and coronary artery disease.’ Several studies have 
documented the strong relation between chronic AF and 
emboli.2J In addition, an increased risk of embolism 
exists in the setting of cardioversion of AF to sinus 
rhythm.4T5 In the best study to date, Bjerkelund and 
Orning6 reported on 572 attempted cardioversions in 437 
patients and observed a 0.8% incidence of embolization in 
long-term anticoagulated patients compared with 5.3% 
in a nonanticoagulated group. Shortcomings of this study 
included lack of randomization, no evaluation of short- 
term therapy and inclusion of arrhythmias such as atria1 
flutter and atria1 tachycardia. Based on such work, cur- 
rent recommendations include anticoagulation for 2 to 4 
weeks before cardioversion to allow adherence and en- 
dothelialization of existing thrombus and 1 to 4 weeks 
after cardioversion to provide coverage for late resump- 
tion of atria1 activity.7s8 The present report evaluates 
these recommendations in light of our experience over the 
past 10 years. 
The University of Michigan Hospital’s Medical In- 
formation Department identified 150 patients with AF 
who underwent cardioversion over the study decade. Af- 
ter 105 patient charts were located from that total, 79 
patients were deemed appropriate for study and 26 were 
excluded. Exclusion criteria included rhythm distur- 
bances other than AF and transient episodes of AF dur- 
ing cardiopulmonary arrest or after cardiac surgery 
(<24 hours). A cerebral embolism was considered pre- 
sent and related to the cardioversion if a circumscribed 
focal deficit developed within 2 weeks of cardioversion.9 
All events occurred, however, within 72 hours. 
Most patients were men (57%) and a significant per- 
centage had underlying organic disease (see later), Age 
ranged from I6 to 84 years. Approximately 14% (11 
patients) had a history of prior stroke or transient ische- 
mic attack. Of those, a third (4 of 11) experienced an 
embolic event at the time of presentation with new onset 
ofAF. Approximately 10% ofpatients had either clinical 
(elevated jugular venous pressure, S3, rales) or radiolog- 
ic evidence of congestive heart failure. One half of the 
study population received digoxin before cardioversion. 
Bundle branch block was found in 10 (13%) patients. 
Duration of AF ranged from <48 hours to >12 
months. It lasted <48 hours in 19 (24%) patients, 48 
hours to 2 weeks in 16 (20%), from 2 weeks to 6 months 
in 24 (30%) and >6 months in 18 (23%). 
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Echocardiograms were performed in 52 of the 79 
patients. Approximately 62% (32 of 52) were found to 
have left atria1 enlargement (>#0 mm). Almost a third 
had mitral (10 of 52) or aortic (6 of 52) valvular abnor- 
malities. Left ventricular dysfunction was found in 31% 
(16 of 52) of these patients. Radionuclide angiograms 
were available in 38% of the study population and ejec- 
tion fractions <45% were documented in 18 patients. 
The majority (93%) was electrically cardioverted (7% 
pharmacologically). Successful conversion to normal si- 
nus rhythm was accomplished in 84% of the patients. 
The duration of sinus rhythm ranged from 12 hours to 
>5 years. 
Sixty-two percent of patients who did not experience 
cardioversion-related emboli were anticoagulated before 
cardioversion, most for <I month. A relatively small 
number (8 of 48) of those who did not experience an 
embolic event received long-term anticoagulation (>I 
year). Criteria for therapeutic anticoagulation included 
a prothrombin time 1.5 to 2.0 times the control values. 
Prothrombin times (by rabbit brain thromboplastin) 
were obtained within 72 hours of cardioversion in all 
patients receiving anticoagulation therapy. Prothrombin 
times were obtained randomly in the 28patients who did 
not receive anticoagulation. 
None of the anticoagulatedpatients had a cardiover- 
sion-related stroke. In contrast, 7% (2 of 28) who were 
not anticoagulated or who received <2 days of heparin 
therapy (“nonanticoagulated group”) had an embolic 
complication. By studying the patients who experienced 
a stroke, a “high-risk” subgroup emerged, comprised of 
patients >55 years who had coronary heart disease, car- 
diomyopathy or hypertension or both, and duration of 
AF >I year. Fifty percent of the nonanticoagulated pa- 
tients in this subgroup had an embolic complication. Five 
others fitting this subgroup definition who received 
short-term anticoagulation had no complications. 
Hemorrhagic complications were seen in 8 patients 
(10%). One patient had only minimal bruising. Seven 
other bleeding events were noted per 16,440 anticoagu- 
lated patient days (0.16 events/patient-year). Specific 
complications included hematuria (2patients), epistaxis 
(2), guaiacpositive stool (I), menorrhagia (1) and diver- 
titular gastrointestinal bleeding (1). Among the 51 pa- 
tients who were anticoagulated, 14% experienced a 
bleeding complication. No hemorrhagic events occurred 
in the 28 patients not anticoagulated. Of note, no bleed- 
ing events were seen among those patients who received 
short-term (<I month) anticoagulation therapy. Hem- 
orrhagic complications occurred almost exclusively in 
the subset of patients receiving long-term anticoagula- 
tion, often necessitated by the presence of prosthetic 
valves. There was no correlation between bleeding com- 
plications and time of cardioversion. No markedly ele- 
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vated prothrombin times were noted during any hemor- 
rhagic event. 
Of the study population overall, 2 patients had peri- 
cardioversion-related embolus (equal to 7% of the non- 
anticoagulated cohort). Both had cardiomegaly, long- 
duration AF (> 1 year) and were either receiving no anti- 
coagulants or had <2 days of heparin therapy. In con- 
trast, no embolic events were observed in the group of 
patients therapeutically anticoagulated. Patients with un- 
derlying organic heart disease and long-standing AF are 
least likely to be successfully cardioverted and main- 
tained in sinus rhythm,lO although in this instance both 
patients were successfully cardioverted. 
The risks of anticoagulation provide strong motivation 
to forego this prophylactic therapy in many patients re- 
quiring cardioversion. Whereas 14% of anticoagulated 
patients in this study experienced a bleeding episode, only 
2% were life-threatening. Of importance is the fact that 
no bleeding complications occurred among patients re- 
ceiving short-term (<l month) anticoagulation in this 
study. Well-managed, short-term anticoagulation of se- 
lected patients appears to be a beneficial prophylactic 
maneuver, with little risk of significant hemorrhagic se- 
quelae. Given the small sample size, this conclusion is still 
presumptive. A large, controlled study would be desirable 
to more definitively assess the utility of anticoagulation in 
this common clinical situation. In the interim, our experi- 
ence supports consideration of short-term anticoagula- 
tion when cardioversion of AF is indicated. 
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Electrophysiologic Effects, Efficacy and Tolerance of Class Ic 
Antiarrhythmic Agents in Wolff -Parkinson-White Syndrome 
Antonis S. Manolis, MD, Deeb N. Salem, MD, and N.A. Mark Estes, III, MD 
A fter extensive evaluation in clinical investigation, the class Ic antiarrhythmic agents flecainide and 
encainide have recently been approved for the treatment 
of ventricular arrhythmias. Preliminary reports indicate 
that these drugs may be useful in the treatment of a 
variety of supraventricular tachycardias, including atrio- 
ventricular reciprocating tachycardia and atria1 tibrilla- 
tion in the setting of Wolff-Parkinson-White (WPW) 
syndrome.1-5 This prospective study was undertaken to 
evaluate systematically the electrophysiologic effects, 
clinical efficacy and tolerance of flecainide and encainide 
in patients with the WPW syndrome. 
Eighteen consecutive patients including 14 men and 4 
women, aged 41 f 18 years (range 20 to 72), with symp- 
tomatic preexcitation syndrome were studied before and 
after oral flecainide or encainide. In 1 patient a con- 
cealed bypass tract was present, while in the remaining 
17 preexcitation was manifest. Presenting symptoms in- 
cluded palpitations in 3 patients, presyncope in 9 pa- 
tients and syncope in 6 patients. The presenting clinical 
arrhythmia was reciprocating tachycardia in 10 patients 
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and atria1 fibrillation in 8 patients. In 2 patients atria1 
fibrillation degenerated into ventricular fibrillation. The 
average number of previous unsuccessful drug trials be- 
y;fz;lr electrophysiologic study was 1.9 f 1 .O 
ran e 
All patients underwent baseline electrophysiologic 
study in the drug-free state. The programmed elec- 
trical stimulation was performed using standard tech- 
niques.4-6 Atrialfibrillation was initiated in all patients 
by rapid burst atrialpacing. After the baseline study, 12 
patients received oralflecainide in dosages of 100 to 200 
mg twice daily for 4 days (mean daily dose 250 f 76 mg) 
and Spatients received oral encainide in doses of 2.5 to 50 
mg thrice daily for 3 days (mean daily dose 108 f 24 
mg) before follow-up evaluation. One patient initially 
placed on encainide had an increase in the frequency of 
reciprocating tachycardia occurrences without prolon- 
gation of the retrograde refractory period of the bypass 
tract. This patient wasswitchedfrom encainide toflecai- 
nide with improved clinical and electrophysiologic re- 
sults. Serum levels of encainide and its metabolites were 
not obtained at follow-up studies. Flecainide serum lev- 
els averaged 0.6 f 0.2 mgjliter (range 0.4 to 0.9). 
All patients were followed clinically at the Cardiac 
Arrhythmia Clinic at 3-month intervals as well as by 
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